Previous 10 | Next 10 |
Biogen’s Alzheimer drug Aducanumab was approve amidst much debate. The Food and Drug Administration (FDA) grants accelerated approvals for drugs to treat serious illnesses for which there are no known, or very few, treatments. Was the drug to be marketed as Aduhelm incorrectly made avai...
Biogen’s Alzheimer drug Aducanumab was approve amidst much debate. The Food and Drug Administration (FDA) grants accelerated approvals for drugs to treat serious illnesses for which there are no known, or very few, treatments. Was the drug to be marketed as Aduhelm incorrectly made avai...
MicroStockHub/iStock via Getty Images After closing up more than 40% yesterday following yesterday's approval of Adhelm (aducanumab) for Alzheimer's, Biogen (BIIB) and Eisai are down in afternoon trading. Biogen is off 3.8%, while Eisai is down 12.1%. Eli Lilly (LLY), which has dona...
Gainers: Clover Health Investments CLOV +70%, Precipio PRPO +15%, GBS (GBS) +15%, PDS Biotechnology PDSB +15%, Cyclerion Therapeutics CYCN +10%.Losers: Ra Medical Systems RMED -19%, HOOKIPA Pharma HOOK -15%, AC Immune (ACIU...
Do You Have These Top Health Care Stocks On Your June 2021 Watchlist? Given the current state of the stock market now, investors may be turning their attention towards health care stocks. For the most part, this could be because of inflation fears quelling the current momentum i...
AC Immune (ACIU) gains 17% premarket after providing updates on its SupraAntigen-derived liposomal vaccine candidates, which are designed to convey active, long-lasting immunization against pathological forms of amyloid-beta (Abeta).The company is advancing an optimized ACI-24 ...
BriaCell Therapeutics (BCTX) +102% after update on the overall survival data of advanced breast cancer patients.Constellation Pharmaceuticals (CNST) +67% on merger agreement with MorphoSys.Stealth BioTherapeutics (MITO) +46% on EMA orphan drug status for elamipretide.AC Immune ...
Optimized vaccine candidate generates enhanced polyclonal antibody response against pyroglutamate Abeta in non-human primates Phase 2 interim analysis of ACI-24 confirms good safety and tolerability profile in people with mild Alzheimer’s disease LAUSANNE, Switzerla...
LAUSANNE, Switzerland, May 20, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will participate in the UBS Global Healthcare Virtual Conference and the Jeff...
AC Immune (ACIU) and its strategic partner Janssen Pharmaceuticals Johnson & Johnson (JNJ) have expanded the ongoing Phase 1b/2a clinical trial of an anti-phosphorylated-Tau (pTau) vaccine candidate ACI-35.030 for the treatment of Alzheimer’s disease ((AD)).The trial expa...
News, Short Squeeze, Breakout and More Instantly...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060,...
2024-05-30 18:30:02 ET BTIG analyst issues BUY recommendation for ACIU on May 30, 2024 04:49PM ET. ACIU was trading at $3.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...
2024-05-30 18:00:07 ET Thomas Shrader from BTIG issued a price target of $8.00 for ACIU on 2024-05-30 16:49:00. The adjusted price target was set to $8.00. At the time of the announcement, ACIU was trading at $3.97. The overall price target consensus is at $10.00 with hi...